Zanubrutinib as Third-Line and Beyond Therapy for FL
Laurie Sehn, MD, discusses recent data on zanubrutinib, a BTK inhibitor, as third-line and beyond therapy for FL.
Laurie Sehn Recent Updates Follicular Lymphoma Mantle Cell Lymphoma Beyond Therapy Third Line Therapy
Source: onclive.com